Innovations for Exceptionally Low-Cost Monoclonal Antibody (mAb) Manufacturing (Option B)
The Gates Foundation and LifeArc* have launched a joint Grand Challenges request for proposals, "Innovations for Exceptionally Low-Cost Monoclonal Antibody (mAb) Manufacturing".
Monoclonal antibodies are one of the most powerful tools in modern medicine. They are highly specific, safe, and effective medicines for a range of conditions, including treating non-communicable diseases and preventing and treating infectious diseases. These biologic therapies already save lives and improve the quality of life for many millions of patients, but high production costs continue to limit access to mAbs, especially for patients in low- and middle-income settings. While there are indication-specific dosage requirements for mAbs, it is broadly understood that to close the equity gap in mAb global access, we need to reach a target cost of $10 per gram of purified, released mAb, a goal long championed by our late colleague, Dr. Steve Hadley, former Senior Program Officer at the Gates Foundation.
This Grand Challenge is calling for proposals that offer radical, innovative, and technically feasible pathways to achieving the $10/gram target. We invite you to bring your expertise, creativity, and passion to this effort and help shape a future where the best medical treatments are available to everyone, everywhere.
The Gates Foundation and LifeArc are collaborating on this request for proposals to support a range of different approaches and build a critical mass of scientific innovation focused on reaching the target. While the organizations will employ a coordinated review process, individual grants will be funded either by the Gates Foundation or by LifeArc.
Applications for proof-of-concept projects (Option A) are due by 11:30 AM. PST on January 31st, 2025.
Additionally, the Gates Foundation is interested in proposals from organizations that have already completed proof-of-concept work with feasible pathways to achieving the $10/gram and are interested in additional support (Option B). Applicants may apply with solutions meeting the criteria for either Option A or Option B, but not both.
Applications for Option B are due by 11:30 AM. PST on May 31st, 2025.
Please review the full details for both opportunities on our Grand Challenges website.
Please contact Jill Sherman at intl.research@lakeheadu.ca for more information.